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Nine children and their mother were exposed to vapors ofmetallic merury. The source ofthe
exposure appears to have been a 6-ozvial ofmercury taken from a neighbor's home. The neigh-
borreportedlyoperated abusinesspreparing mercury-filledamulets forpractitioners ofthe Afro-
Caribbean religion Santeria. At diagnosis, urinary mercurylevels in the children ranged from 61
to 1,213 pgg creatinine, with a geometric mean of214.3 pg creatinine. All of the children
were asymptomatic To prevent development ofneurotoxicity, we treated the children with oral
meso-2,3-dimercaptosuccnc acid (DMSA). Duringchelation, the geometric mean urine level rose
initially by268% to 573.2 pgmercury/g creatinine (p < 0.0005). Atthe6-week follow-up exami-
nation after treatment, the geometric mean urine mercury level had fallen to 102.1 pg/g creati-
nine, whichwas 17.8% ofthe geometric mean level observed during treatment (p < 0.0005) and
47.6% oftheoriginal baseline level (p < 0.001). Thus, oralchelationwith DMSAproduced asig-
nificant mercury diuresis in these children. We observed no adverse side effects oftreatment.
DMSAappears to be an effective andsafe chelating agent for treatment ofpediati overexosure
to metallic mercury. KAywork children,2,3-dinaerpto-1-propanesulfonicacid, DMPS, DMSA,
meso-2,3-dimercaptosuccinic acid, metallic mercury, overexposure, treatment. Environ Health
Prspect108:575-577 (2000). [Online 5 May2000]
bap:/Iehpnl.niehs.nih.govldocsl20o0/108p575-577formanlabstraca.hsm
Case Presentation
In January and February 1998, nine children
(in one family) and their mother were
exposed to vapors of metallic mercury in
their apartment in Yonkers, New York. The
apparent source was a neighbor's business,
where mercury-filled amulets were reportedly
prepared for practitioners of the Afro-
Caribbean religion Santeria. The oldest child
found a 6-oz vial of mercury on the neigh-
bor's porch. Over the next several days, the
children played a game in which they hit a
large globule ofmercury with a hammer and
observed its dispersion across awooden floor.
Mercury was then tracked throughout the
apartment. The mother attempted over the
next week to remove the mercurywith a vac-
uum deaner, butonlydispersed it further.
The mother took the children to a pedia-
trician in Yonkers, who promptly obtained
urine samples for mercury analysis. After
finding elevated levels ofmercury in the sam-
ples, he referred the children to the Pediatric
Environmental Health Specialty Unit of the
Mount Sinai Hospital where all nine were
hospitalized. On admission, we did not
detect tremor, other neurologic abnormalities,
or other signs ofmercury poisoning in any of
the children. To prevent development of
neurotoxicity, we initiated treatment of all
nine children with oral meso-2,3-dimercapto-
succinic acid (DMSA). We collected 24-hr
urine samples for mercury and creatinine
determinations on each child throughout the
admission and periodically afterdischarge.
Pretreatment urinary mercury levels
ranged from 61 to 1,213 pg/g creatinine,
with a geometric mean of214.3 pg/g creati-
nine (Figure 1); the upper limit of normal
recommended by the World Health Organi-
zation (WHO) is 50 pg mercury/g creatinine
(1). Initially, the children were treated with
30 mg/kg/day DMSA for 5 days. The geo-
metric mean of all measurements obtained
during inpatient chelation rose by 268%
above baseline to 573.2 pg mercury/g creati-
nine (p < 0.0005). The children were then
discharged and continued to receive treat-
ment with 20 mg/kg/day DMSA at home for
2 more weeks. Six weeks after discharge all
nine children showed reduced urine mercury
levels ranging from 71 to 239 pg/g creatinine.
The geometric mean ofthese follow-up levels
(day 54 after initial chelation) was 102.1 pg
mercury/g creatinine, which was 17.8% of
the geometric mean level during inpatient
treatment (p < 0.0005) and 47.6% of the
baseline level (p < 0.001). Because the follow-
up values still exceeded 50 pg mercury/g crea-
tinine, we prescribed an additional 2-week
course ofDMSA for all nine children. Urine
mercury levels obtained several months later
(day 261 after initial chelation) had dropped
to 27.4 pg/g creatinine. At this point, two of
the children (cases #3 and #4) still had levels
> 50 pg mercury/g creatinine, and they
received a final course of DMSA chelation.
We learned that the family, who had been
relocated, had brought along a mercury-cont-
aminated couch from their old apartment.
This source, which may have contributed to
the two persistently elevated levels, was
removed. Twelve months after initial chela-
tion, urine mercury levels in these two chil-
drenwere 11 and9 pg/gcreatinine (Table 1).
Discussion
Metallic mercury is toxic to the nervous sys-
tem, kidneys, and skin (2). The neurologic
manifestations ofhigh-dose poisoninginclude
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tremor as well as pathologic shyness, memory
loss, delusions, and hallucinations. This neu-
rologic syndrome, termed erethism, is seen
most commonly in workers with poorly con-
trolled, high-dose occupational exposure to
metallic mercury (3). At lower levels ofexpo-
sure, metallic mercury causes subdinical neu-
rologic injury characterized by shortened
attention span and decreased intelligence (4).
In the kidneys, metallic mercury causes pro-
teinuria, nephrotic syndrome, and, in extreme
cases, renal failure. In children, metallic mer-
cury can cause acrodynia, a syndrome charac-
terized byswelling and erythema ofthe hands
and feet, with bright pink peeling skin, espe-
cially on the tips ofthefingers and toes (5).
Although detailed studies ofsubtle neuro-
logic effects ofmetallic mercury overexposure
in children are not available, it seems reason-
able to anticipate that children are at higher
risk oftoxicity than adults are. Children's pat-
terns ofplay are near the ground, and their
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normal oral exploratory behavior increases
their risk ofexposure. Children's nervous sys-
tems are undergoing rapid development and
differentiation, and the developmental process
is easily disrupted by toxic exposures (6). In
addition, children have a natural fascination
with the liquid properties ofmetallic mercury.
The information available on the detrimental
neurologic effects to children oflow-level lead
exposure (7,8) heightens concern about the
potential ofmetallic mercury to be a pediatric
neurotoxin atrelativelylow-doseexposure.
Inhalation is the most common route of
pediatric exposure to metallic mercury. At
room temperature, mercury exerts a signifi-
cant vapor pressure, and approximately 80%
of inhaled mercury vapor is retained in the
body (9). Infants and young children are at
particularly high risk ofexposure to mercury
vapor because they tend to play near to the
ground where the heavier-than-air vapor set-
tles (10). Neither ingestion nor percutaneous
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Figure 1. Geometric mean urine mercury levels in nine metallic mercury-overexposed children chelated
with DMSA. Tx,treatment.
Spot urine samples. b24-hr collections.
absorption are important routes ofexposure,
and swallowed metallic mercury is poorly
absorbed from the gut. Mercury readily
crosses theplacenta, and levels in mother and
fetus arevirtuallyidentical.
Potential sources of metallic mercury
exposure for children include
* Household contamination with mercury
that has been brought into the home from
a school or place ofwork; such household
contamination maybeespeciallydangerous
in mobile homes because of their poor
interiorventilation
* Latex paint containing a mercury fungi-
cide; pediatric exposure to such paint has
been reported to cause acrodynia (11)
* Residence in mercury-contaminated former
factory buildings that have been converted
to loft apartments (12)
* Exposure to liquid mercury that is used in
some cultures forreligious ormedicinal pur-
poses. Metallic mercury has been reported
to be used for these purposes by the some
members ofthe Latino and Afro-Caribbean
Communities in NewYorkCity(13).
Treatment ofmetallic mercury poisoning
had until recently been limited to two
options, both relatively unsatisfactory: British
anti-lewisite (BAL) or D-penicillamine. The
utility of BAL is limited in children by the
need for repeated, painful deep muscular
injections and also by the propensity ofBAL
to accelerate redistribution of mercury in
body tissues, particularly to the brain; thus
BAL can potentially aggravate systemic toxic-
ity (14,15). Use ofD-penicillamine is limited
by its high incidence of allergic reactions,
including cross-reactions with penicillin (16).
More recently, two oral chelating agents
have become available in the United States:
DMSA and 2,3-dimercapto-1-propane sul-
fonic acid (DMPS) (17,18). These com-
pounds are chemical analogs ofBAL. Because
these compounds are absorbed from the gas-
trointestinal tract, both can be administered
orally. Both have shown efficacy in animals
as well as in humans in increasing the urinary
excretion ofmercury (16-21). The Food and
Table 1. Urine mercury levels (pg mercury/g creatinine) in nine metallic mercury-overexposed children treated with DMSA.
Days oftreatmenta Follow-up visits
Pt ID Ptage Pre Tx Day 1 Day 2 Day3 Day4 Day 5 Day54 Day261 12 Months
1 5.5 174 221 b 560 581 580 106 15
2 4.5 125 168 775 425 420 738 71 43
3 1.5 439 649 b 1,857 2,266 1,125 123 187 11
4 1.5 1,213 427 419 1,223 551 924 239 62 9
5 0.25 130 109 293 b 439 628 77 35
6 12 476 b b 506 b b 132 13
7 12 236 439 b b 230 581 77 15
8 7.5 83 494 480 b 552 708 95 17
9 13.5 68 b 1,338 374 353 347 73 10
GMC 214.3 304.6 571.8 683.9 527.5 668.5 102.1 27.4
Abbreviations: GM, geometric mean; Pt, patient, Tx,treatment. aDays 1-5 are 24-hr urine collections; all other days are spot urine levels. bMissing data elements are due to damaged labels or lost specimens. CGM of all on-treatment values (days
1-5) = 573.2 50 pg mercury/g creatinine.
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Drug Administration has, to date, licensed
DMSA only for treatment of pediatric lead
poisoning.
This paper represents, to our knowledge,
the largest published clinical case series
describing the use of oral DMSA for the
treatment of overexposure to metallic mer-
cury in children. Our data on the rapid
increase ofmercury diuresis immediately fol-
lowing initiation of oral chelation therapy
with DMSA argue that DMSA is an effective
chelating agent for treatment of pediatric
overexposure to mercury. Without treat-
ment, the children would be expected to
undergo a much slower diuresis, with steadily
declining urine mercury levels over a period
that is consistent with the half-life ofmetallic
mercury (roughly 1-2 months) (22). These
data are also consistent with previous studies
that showed DMSA to be efficacious in the
treatment ofmercury poisoning in both ani-
mals andhumans (19-21).
Our study contained no untreated com-
parison group. Although it would have been
interesting scientifically to compare mercury
diuresis between treated and untreated chil-
dren, the threat of neurotoxicity was too
great in these children, with their highly ele-
vated urine mercury levels, to justify with-
holding DMSA.
We would, ideally, have wished to com-
pare DMSA to DMPS in this study tojudge
the relative efficacy of these two chelating
agents in treatment of metallic mercury
overexposure. The International Programme
on Chemical Safety (IPCS) of the WHO
has recommended that DMPS be consid-
ered the "drug of first choice for cases of
acute poisoning with inorganic mercury
(17)-. The IPCS also notes, however, that
DMPS is somewhat more toxic than DMSA
and that DMSA is also effective against
mercury. Unfortunately, DMPS was not
immediately available to us in this situation,
whereas DMSA was readily accessible
-through. the hospital pharmacy because of
its widespread use as a chelating agent
against lead poisoning.
Urine is the body fluid of choice for
assessing exposure to metallic mercury. It
provides a much more valid index ofrecent
exposure than the blood mercury level.
However, it is important to adjust the urine
mercury level for creatinine concentration.
This was illustrated dramatically in the
mother ofthese nine children, a 31-year-old
woman with poorly controlled diabetes and
consequent wide swings in urine volume
and concentration. She had two urine
samples collected within 24 hr at the time
of the children's initial hospitalization. Her
unadjusted mercury levels were 6.1 ng/mL
(sample #1) and 137.4 ng/mL (sample #2), a
22-fold variation. However, when corrected
for urinary creatinine concentration, the
adjusted levels were 22 pg mercury/g creati-
nine and 45 pg mercury/g creatinine, nearly
equivalent values and both < 50 pg mer-
cury/g creatinine.
An unresolved issue in the medical man-
agement ofpediatric metallic mercury expo-
sure is the level of mercury in urine that
should be considered a trigger for initiation
ofchelation therapy. Symptoms of metallic
mercury poisoning may first appear in
children at mercury levels of 50-100 pg/g
creatinine, and tremor is typically the first
symptom observed (23). Unfortunately,
detailed epidemiologic studies such as those
undertaken to assess dose-response relation-
ships in subclinical lead poisoning in chil-
dren (7,8,24) have not yet been performed
in the case ofsubdinical mercury exposure.
Therefore, we recommend that treatment
should be initiated in children with urine
mercury levels 2 50 pg/g creatinine, as rec-
ommended by the WHO (1). This recom-
mendation should be refined through
furtherstudy.
Another unresolved question is whether
the manifestations of mercury intoxication
can be reversed by chelation therapy. Pre-
liminary studies in occupationally exposed
adults suggest that the effects of adult mer-
cury poisoning are reversible with treatment
(25). However, extensive studies of the
chronic effects of lower level metallic mer-
cury poisoning have not been undertaken in
adults, and even less research has been done
in children. Therefore, we recommend that
chelation therapy be administered as soon as
possible after the diagnosis ofoverexposure
to metallic mercury in the hope that it will
minimize the long-term impact of mercury
intoxication, although the effectiveness of
this method has not been proven. Ifpossible,
neurodevelopmental testing may be indicat-
ed at the time of exposure and periodically
afterward to assess the possibility ofresidual
neurobehavioral impairment.
Conclusion
This case along with other recent cases of
pediatric poisoning with metallic mercury
remind us ofthe importance ofprimary pre-
vention of mercury exposure. Overexposure
to mercury is not a rare occurrence. Steps
should be taken to limit the availability of
mercury. Pediatric practitioners should warn
parents and children about the hazards of
playing with this perennially attractive but
always dangerous metal. If exposure to
metallic mercury is suspected, urine samples
should be obtained for both mercury and
creatinine determinations. Children with
urine mercury levels > 50 pg/g creatinine
should be considered for oral chelation even
ifthey are asymptomatic.
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